$NURO
NeuroMetrix, Inc.

2015 Q3 Form 10-Q Financial Statement

#000114420415043943 Filed on July 23, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $2.054M $1.225M $1.344M
YoY Change 43.89% -8.84% 15.8%
Cost Of Revenue $1.119M $595.0K $655.3K
YoY Change 75.14% -9.2% 30.76%
Gross Profit $935.2K $630.0K $688.4K
YoY Change 18.57% -8.49% 4.42%
Gross Profit Margin 45.52% 51.43% 51.23%
Selling, General & Admin $3.352M $2.987M $1.843M
YoY Change 81.39% 62.08% -1.57%
% of Gross Profit 358.39% 474.18% 267.7%
Research & Development $940.8K $982.3K $1.465M
YoY Change -0.48% -32.94% 60.29%
% of Gross Profit 100.59% 155.92% 212.78%
Depreciation & Amortization $60.00K $70.00K $40.00K
YoY Change 100.0% 75.0% 0.0%
% of Gross Profit 6.42% 11.11% 5.81%
Operating Expenses $4.293M $3.969M $3.308M
YoY Change 53.68% 20.0% 18.72%
Operating Profit -$3.357M -$3.339M -$2.619M
YoY Change 67.5% 27.49% 23.15%
Interest Expense $150.0K $2.140M $480.0K
YoY Change -73.68% 345.83% -58.62%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change -100.0%
Pretax Income -$3.200M -$1.200M -$2.170M
YoY Change 119.18% -44.7% 60.74%
Income Tax
% Of Pretax Income
Net Earnings -$3.204M -$1.203M -$2.171M
YoY Change 119.18% -44.57% 61.29%
Net Earnings / Revenue -155.94% -98.22% -161.54%
Basic Earnings Per Share
Diluted Earnings Per Share -$80.00M -$40.00M -$72.33M
COMMON SHARES
Basic Shares Outstanding 11.04M shares 8.519M shares 5.946M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.120M $12.64M $13.69M
YoY Change -21.98% -7.67% 42.75%
Cash & Equivalents $9.120M $12.64M $13.69M
Short-Term Investments
Other Short-Term Assets $880.0K $550.0K $350.0K
YoY Change 100.0% 57.14% 9.38%
Inventory $1.070M $1.220M $600.0K
Prepaid Expenses
Receivables $900.0K $590.0K $530.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $11.97M $15.00M $15.18M
YoY Change -10.47% -1.19% 35.35%
LONG-TERM ASSETS
Property, Plant & Equipment $750.0K $810.0K $180.4K
YoY Change 278.7% 348.97% -21.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $210.0K $220.0K $0.00
YoY Change
Total Long-Term Assets $960.0K $1.030M $181.7K
YoY Change 379.89% 466.85% -22.24%
TOTAL ASSETS
Total Short-Term Assets $11.97M $15.00M $15.18M
Total Long-Term Assets $960.0K $1.030M $181.7K
Total Assets $12.93M $16.03M $15.36M
YoY Change -4.72% 4.35% 34.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $950.0K $880.0K $534.5K
YoY Change 82.69% 64.63% 154.54%
Accrued Expenses $1.900M $1.870M $977.2K
YoY Change -4.52% 91.37% -7.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.538M $3.360M $2.370M
YoY Change 38.74% 41.77% 12.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $900.0K $1.050M $5.380M
YoY Change -81.29% -80.48% 85.52%
Total Long-Term Liabilities $900.0K $1.050M $5.380M
YoY Change -81.29% -80.48% 85.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.538M $3.360M $2.370M
Total Long-Term Liabilities $900.0K $1.050M $5.380M
Total Liabilities $4.438M $4.410M $7.750M
YoY Change -39.78% -43.1% 54.75%
SHAREHOLDERS EQUITY
Retained Earnings -$160.9M
YoY Change 6.2%
Common Stock $1.379K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.490M $11.62M $7.610M
YoY Change
Total Liabilities & Shareholders Equity $12.93M $16.03M $15.36M
YoY Change -4.71% 4.36% 34.16%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$3.204M -$1.203M -$2.171M
YoY Change 119.18% -44.57% 61.29%
Depreciation, Depletion And Amortization $60.00K $70.00K $40.00K
YoY Change 100.0% 75.0% 0.0%
Cash From Operating Activities -$3.430M -$3.550M -$1.830M
YoY Change 79.58% 93.99% -1.61%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K -$320.0K -$20.00K
YoY Change 80.0% 1500.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.00K -$320.0K -$20.00K
YoY Change 80.0% 1500.0% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 10.11M 7.960M
YoY Change -100.0% 27.01% 73.8%
NET CHANGE
Cash From Operating Activities -3.430M -3.550M -1.830M
Cash From Investing Activities -90.00K -320.0K -20.00K
Cash From Financing Activities 0.000 10.11M 7.960M
Net Change In Cash -3.520M 6.240M 6.110M
YoY Change 76.0% 2.13% 125.46%
FREE CASH FLOW
Cash From Operating Activities -$3.430M -$3.550M -$1.830M
Capital Expenditures -$90.00K -$320.0K -$20.00K
Free Cash Flow -$3.340M -$3.230M -$1.810M
YoY Change 79.57% 78.45% -2.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9221656 shares
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31863894 shares
CY2015Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
674553 USD
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
209426 USD
CY2015Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
547047 USD
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
470314 USD
CY2015Q2 nuro Technology Fees
TechnologyFees
450000 USD
CY2014Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
218534 USD
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
257024 USD
CY2015Q2 nuro Clinical Study Obligations
ClinicalStudyObligations
68000 USD
CY2014Q4 nuro Clinical Study Obligations
ClinicalStudyObligations
74000 USD
CY2015Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
70573 USD
CY2014Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
34206 USD
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
85569 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
212137 USD
CY2015Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8652998 USD
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4107478 USD
CY2015Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
8652998 USD
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
4107478 USD
CY2015Q2 nuro Common Stock Warrants Fair Value Disclosure
CommonStockWarrantsFairValueDisclosure
1041911 USD
CY2014Q4 nuro Common Stock Warrants Fair Value Disclosure
CommonStockWarrantsFairValueDisclosure
5307332 USD
CY2015Q2 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
1041911 USD
CY2014Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
5307332 USD
CY2015Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
2500000 USD
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2016-01-15
CY2015Q2 nuro Restricted Cash Collateral Letters Of Credit
RestrictedCashCollateralLettersOfCredit
226731 USD
CY2015Q2 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
2300000 USD
CY2014Q1 nuro Closing Price Of Shares
ClosingPriceOfShares
2.45
CY2015Q1 nuro Closing Price Of Shares
ClosingPriceOfShares
1.69
us-gaap Revenues
Revenues
2675307 USD
us-gaap Revenues
Revenues
2507947 USD
CY2014Q2 us-gaap Revenues
Revenues
1343770 USD
CY2015Q2 us-gaap Revenues
Revenues
1224987 USD
us-gaap Cost Of Revenue
CostOfRevenue
1270418 USD
us-gaap Cost Of Revenue
CostOfRevenue
1232293 USD
CY2014Q2 us-gaap Cost Of Revenue
CostOfRevenue
655337 USD
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
595032 USD
us-gaap Gross Profit
GrossProfit
1404889 USD
us-gaap Gross Profit
GrossProfit
1275654 USD
CY2014Q2 us-gaap Gross Profit
GrossProfit
688433 USD
CY2015Q2 us-gaap Gross Profit
GrossProfit
629955 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2328551 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1884795 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1464834 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
982253 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1140880 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3217968 USD
CY2014Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
694664 USD
CY2015Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1762282 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2295035 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2770912 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1148278 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1224822 USD
us-gaap Operating Expenses
OperatingExpenses
5764466 USD
us-gaap Operating Expenses
OperatingExpenses
7873675 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
3307776 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
3969357 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4359577 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6598021 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2619343 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3339402 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
2026 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
1589 USD
CY2014Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
990 USD
CY2015Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
500 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-989861 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3321998 USD
CY2014Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-475261 USD
CY2015Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2135696 USD
us-gaap Net Income Loss
NetIncomeLoss
-3395308 USD
us-gaap Net Income Loss
NetIncomeLoss
-3274434 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2170710 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-1203206 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5966929 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8734185 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6002330 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9189231 shares
us-gaap Depreciation And Amortization
DepreciationAndAmortization
66293 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
95486 USD
us-gaap Share Based Compensation
ShareBasedCompensation
137164 USD
us-gaap Share Based Compensation
ShareBasedCompensation
172402 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
141915 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8446 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
41030 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
541860 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-65028 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
165454 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
211636 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
262191 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
636551 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5032 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-21028 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
587139 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3444852 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6189942 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17392 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
503028 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17392 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-503028 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4498039 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3416997 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9195753 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13693792 USD
nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
-104405 USD
nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
-281757 USD
CY2015Q2 nuro Accrued Personnel Related Obligations
AccruedPersonnelRelatedObligations
80859 USD
CY2014Q4 nuro Accrued Personnel Related Obligations
AccruedPersonnelRelatedObligations
37761 USD
CY2015Q2 nuro Accrued Federal Excise Tax
AccruedFederalExciseTax
26716 USD
CY2014Q4 nuro Accrued Federal Excise Tax
AccruedFederalExciseTax
25989 USD
CY2015Q2 nuro Accrued Consulting Fees
AccruedConsultingFees
240906 USD
CY2014Q4 nuro Accrued Consulting Fees
AccruedConsultingFees
173759 USD
CY2014Q4 us-gaap Restructuring Reserve
RestructuringReserve
148921 USD
us-gaap Restructuring Reserve Accrual Adjustment
RestructuringReserveAccrualAdjustment
0 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
148921 USD
CY2015Q2 us-gaap Restructuring Reserve
RestructuringReserve
0 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
NeuroMetrix, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001289850
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
NURO
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11040959 shares
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10996408 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10996408 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3614.357 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3614.357 shares
CY2015Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2014Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
27618 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-27618 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
27618 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13316324 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7960283 USD
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
3206357 USD
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10109967 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7960283 USD
nuro Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
nuro Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
4418824 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2 us-gaap Deferred Revenue
DeferredRevenue
573000 USD
CY2015Q2 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
320000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2014Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
664600 shares
CY2014Q2 us-gaap Share Price
SharePrice
2.04
CY2014Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3921569 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.04
CY2014Q2 nuro Gross Proceeds From Issuance Or Sale Of Equity
GrossProceedsFromIssuanceOrSaleOfEquity
8000000 USD
CY2014Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7900000 USD
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1000
CY2014Q2 nuro Class Of Warrant Or Right Exercisable Period
ClassOfWarrantOrRightExercisablePeriod
P5Y
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4753901 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5126378 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6825129 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6350976 USD
CY2015Q2 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
4140446 USD
CY2014Q2 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
2955668 USD
nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
4140446 USD
nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
2955668 USD
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
402000 USD
CY2015Q2 nuro Warrants Fair Value Disclosure
WarrantsFairValueDisclosure
943423 USD
CY2015Q2 nuro Return Of Capital To Common Shareholders Attributable From Repurchase Of Preferred Shares And Related Embedded Beneficial Conversion Features
ReturnOfCapitalToCommonShareholdersAttributableFromRepurchaseOfPreferredSharesAndRelatedEmbeddedBeneficialConversionFeatures
589751 USD
CY2014Q2 nuro Return Of Capital To Common Shareholders Attributable From Repurchase Of Preferred Shares And Related Embedded Beneficial Conversion Features
ReturnOfCapitalToCommonShareholdersAttributableFromRepurchaseOfPreferredSharesAndRelatedEmbeddedBeneficialConversionFeatures
0 USD
nuro Return Of Capital To Common Shareholders Attributable From Repurchase Of Preferred Shares And Related Embedded Beneficial Conversion Features
ReturnOfCapitalToCommonShareholdersAttributableFromRepurchaseOfPreferredSharesAndRelatedEmbeddedBeneficialConversionFeatures
589751 USD
nuro Return Of Capital To Common Shareholders Attributable From Repurchase Of Preferred Shares And Related Embedded Beneficial Conversion Features
ReturnOfCapitalToCommonShareholdersAttributableFromRepurchaseOfPreferredSharesAndRelatedEmbeddedBeneficialConversionFeatures
0 USD
CY2015Q2 nuro Number Of Warrants Repurchased
NumberOfWarrantsRepurchased
1571744 shares

Files In Submission

Name View Source Status
0001144204-15-043943-index-headers.html Edgar Link pending
0001144204-15-043943-index.html Edgar Link pending
0001144204-15-043943.txt Edgar Link pending
0001144204-15-043943-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nuro-20150630.xml Edgar Link completed
nuro-20150630.xsd Edgar Link pending
nuro-20150630_cal.xml Edgar Link unprocessable
nuro-20150630_def.xml Edgar Link unprocessable
nuro-20150630_lab.xml Edgar Link unprocessable
nuro-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v415450_10q.htm Edgar Link pending
v415450_ex10-1.htm Edgar Link pending
v415450_ex31-1.htm Edgar Link pending
v415450_ex31-2.htm Edgar Link pending
v415450_ex32.htm Edgar Link pending
v415450_ex4-1.htm Edgar Link pending